Pharma Business review -

Pharma Business review is using cookies

Continue Learn More

Close

October 22, 2018

Lynparza reduces disease progression risk in ovarian cancer study

A phase III trial has demonstrated that Lynparza maintenance therapy reduced risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer.

Image: AstraZeneca and Merck’s Lynparza has reduced risk of disease progression or death in ovarian cancer study. Photo: courtesy of AstraZeneca.

October 19, 2018

Novartis to acquire biopharmaceutical firm Endocyte for $2.1bn

Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of Novartis AG.

October 18, 2018

Diurnal puts hold on US development of adrenal drug Chronocort

Image: Diurnal will suspend the US development of adrenal drug Chronocort. Photo: courtesy of jk1991 / FreeDigitalPhotos.net.

Contracts

October 8, 2018

hVIVO signs new contracts with global biopharmaceutical firm

Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.

Opiant signs contract with BARDA to accelerate OPTN003 product development

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Drug Manufacturing

Data science company IXICO extends contract with biopharmaceutical firm

Deals

Deals October 17, 2018

US firm Revolution Medicines buys Warp Drive Bio

Pharmaceutical Business Review

Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India

Alliqua BioMedical, Adynxx enter into merger deal

Mundipharma buys Spanish biosimilars company Cinfa Biotech

Popular

Videos

Suppliers

Spotlight

Pharmaceutical Business Review

Alliqua BioMedical, Adynxx enter into merger deal

Pharmaceutical Business Review

Mereo completes patient enrollment for brittle bone disease trial

Pharmaceutical Business Review

AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer